Centuple Global

Why is Checkpoint Trends Ltd falling/rising?

As of 09-Jun, Centuple Global Ltd's stock price is at 42.99, down 1.4%, and has underperformed its sector. The stock has declined 62.38% year-to-date, despite a strong one-year return of 135.56%, indicating a bearish trend.

As of 09-Jun, Centuple Global Ltd's stock price is falling, currently at 42.99, reflecting a change of -0.61 (-1.4%). The stock has underperformed its sector by 2.19% today and has experienced consecutive declines over the last two days, totaling a drop of 2.6%. Additionally, the stock is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a bearish trend. <BR><BR>In terms of broader performance, the stock has seen a significant year-to-date decline of 62.38%, compared to a 13.26% drop in the benchmark Sensex. Despite a strong one-year return of 135.56%, the recent trends suggest a challenging environment for the stock. However, there is a slight positive note with a 33.95% increase in delivery volume on June 8, indicating rising investor participation, but this has not been enough to counteract the overall downward movement in the stock price.

Which are the latest news on Centuple Global?

Should I buy, sell or hold Checkpoint Trends Ltd?

Are Checkpoint Trends Ltd latest results good or bad?

Checkpoint Trends Ltd's latest results show impressive revenue growth of 111,664% year-over-year, reaching ₹279.41 crores, but the company reported a net loss of ₹0.48 crores and negative operating margins, raising concerns about its profitability and financial sustainability. Investors should be cautious and monitor the company's ability to improve margins in future quarters.

The latest results for Checkpoint Trends Ltd (formerly Centuple Global) present a mixed picture. On one hand, the company has achieved remarkable revenue growth, with net sales soaring by 111,664% year-over-year, reaching ₹279.41 crores in Q4 FY26. This significant increase indicates a successful scaling of operations and a dramatic transformation from previous years.<BR><BR>However, the financial performance is marred by a net loss of ₹0.48 crores for the quarter, a stark contrast to the profit of ₹0.06 crores reported in the same quarter last year. This represents a concerning decline in profitability, especially given that the operating margin has turned negative at -0.14%, down from 36.0% the previous year. The company's inability to convert its substantial revenue growth into profits raises questions about the sustainability of its business model.<BR><BR>Additionally, the return on equity (ROE) is notably high at 104.42%, but this figure must be interpreted cautiously due to the minimal equity base and the recent losses. The overall financial health appears precarious, with operational challenges evident in the negative operating profit before depreciation, interest, and tax (PBDIT) of ₹-0.38 crores.<BR><BR>In summary, while the explosive revenue growth is a positive sign, the company's current financial results reflect significant challenges in achieving profitability, making the overall outlook quite concerning. Investors should be cautious and closely monitor the company's ability to recover margins in the upcoming quarters.

When is the next results date for Checkpoint Trends Ltd?

The next results date for Checkpoint Trends Ltd is 30 May 2026.

The next results date for Checkpoint Trends Ltd is scheduled for 30 May 2026.

Is Checkpoint Trend overvalued or undervalued?

As of November 13, 2025, Checkpoint Trend is considered undervalued with a favorable valuation grade shift, featuring a PE ratio of 30.19 and a year-to-date return of 512.18%, significantly outperforming its peers and the Sensex.

As of 13 November 2025, Checkpoint Trend's valuation grade has moved from very expensive to attractive, indicating a significant shift in its market perception. The company is currently assessed as undervalued, particularly in light of its impressive financial metrics. Key ratios include a PE ratio of 30.19, an EV to EBITDA ratio of 22.62, and a PEG ratio of 0.04, which suggests strong growth potential relative to its price.<BR><BR>In comparison to its peers, Checkpoint Trend's valuation appears favorable. For instance, Sun Pharma has a PE ratio of 36.15 and an EV to EBITDA of 23.85, while Cipla, which is also rated attractive, has a PE of 22.65. Notably, Checkpoint Trend's return performance has significantly outpaced the Sensex, with a year-to-date return of 512.18% compared to the Sensex's 8.11%, reinforcing the notion that the stock is undervalued relative to its growth trajectory.

How has been the historical performance of Checkpoint Trend?

Checkpoint Trend's historical performance shows a decline in net sales from 2.01 Cr in Mar'22 to 0.50 Cr in Mar'25, with total operating income and expenditures also decreasing. However, operating profit improved from a loss in Mar'23 to a profit in Mar'25, while total assets and liabilities decreased, indicating a stagnant cash position.

Answer:<BR>The historical performance of Checkpoint Trend shows a fluctuating trend in net sales and profitability over the years.<BR><BR>Breakdown:<BR>Checkpoint Trend's net sales have seen a decline from 2.01 Cr in Mar'22 to 0.50 Cr in Mar'25, with a notable drop from 1.16 Cr in Mar'23. The total operating income followed a similar trend, decreasing from 2.01 Cr in Mar'22 to 0.50 Cr in Mar'25. The company's total expenditure, excluding depreciation, also decreased from 2.03 Cr in Mar'22 to 0.44 Cr in Mar'25. Operating profit (PBDIT) showed a slight improvement, moving from a loss of 0.08 Cr in Mar'23 to a profit of 0.06 Cr in Mar'25. Profit before tax improved from a loss of 0.08 Cr in Mar'23 to a profit of 0.05 Cr in Mar'25, while profit after tax remained stable at 0.03 Cr for both Mar'24 and Mar'25. The company's total assets decreased from 0.93 Cr in Mar'24 to 0.65 Cr in Mar'25, and total liabilities also declined from 0.93 Cr to 0.65 Cr in the same period. Cash flow figures indicate no cash inflow or outflow across the years, reflecting a stagnant cash position.

Who are the top shareholders of the Checkpoint Trend?

The top shareholders of Checkpoint Trend are individual investors with 71.77% of shares, followed by Religare Finvest Ltd at 5.89%, and two foreign institutional investors holding a combined 10.85%. There are no pledged promoter holdings or mutual funds in the shareholding structure.

The top shareholders of Checkpoint Trend include individual investors, who hold a significant 71.77% of the shares. Additionally, Religare Finvest Ltd is the highest public shareholder with a stake of 5.89%. The company also has two foreign institutional investors (FIIs) holding a combined 10.85%. There are no pledged promoter holdings or mutual funds involved in the shareholding structure.

What is the technical trend for Checkpoint Trend?

As of May 29, 2025, Checkpoint Trend shows a mildly bullish outlook, supported by daily moving averages and monthly KST, despite some short-term bearish signals from weekly MACD and RSI.

As of 29 May 2025, the technical trend for Checkpoint Trend has changed from bullish to mildly bullish. The current stance is mildly bullish, driven by the daily moving averages indicating mild bullishness and the monthly KST remaining bullish. However, the weekly MACD and RSI are showing mildly bearish and bearish signals respectively, which temper the overall bullish outlook. The Bollinger Bands are also indicating mild bullishness on both weekly and monthly time frames. Overall, while there are some bearish signals in the short term, the longer-term indicators suggest a cautiously optimistic view.

how big is Checkpoint Trend?

As of Jun 06, Checkpoint Trends Ltd has a market capitalization of 10.00 Cr, with recent net sales of 0.50 Cr and a net profit of 0.02 Cr over the last four quarters. Shareholder's funds are 0.53 Cr, and total assets are 0.93 Cr as of Mar'24.

Market Cap: As of Jun 06, Checkpoint Trends Ltd has a market capitalization of 10.00 Cr, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters, which includes Mar'25, Dec'24, Sep'24, and Jun'24, is 0.50 Cr. The sum of Net Profit for the same quarters is 0.02 Cr. This data is presented on a Standalone basis.<BR><BR>Balance Sheet Snapshot: This is Standalone data for the latest annual period ending in Mar'24. The Shareholder's Funds are reported at 0.53 Cr, while Total Assets amount to 0.93 Cr.

Who are in the management team of Checkpoint Trend?

As of March 2022, the management team of Checkpoint Trend includes Abha Kapoor (CFO), Sunil Khandelwal (Managing Director), Ritu Chhatani (Company Secretary), and independent directors Sneha Thakur, Gopal Sahu, and Harish Surve, who oversee operations and compliance.

As of March 2022, the management team of Checkpoint Trend includes the following members:<BR><BR>1. Abha Kapoor - Director (Finance) & CFO<BR>2. Sneha Thakur - Independent Director<BR>3. Sunil Khandelwal - Managing Director<BR>4. Gopal Sahu - Independent Director<BR>5. Ritu Chhatani - Company Secretary & Compliance Officer<BR>6. Harish Surve - Independent Director<BR><BR>This team is responsible for overseeing the company's operations and ensuring compliance with regulations.

What does Checkpoint Trend do?

Checkpoint Trends Ltd is a Micro Cap company in the Pharmaceuticals & Biotechnology sector, providing trading and consulting services. As of March 2025, it reported net sales and net profit of 0 Cr, with a market cap of Rs 9 Cr.

Overview: <BR>Checkpoint Trends Ltd is engaged in the business of trading and provides various consulting services within the Pharmaceuticals & Biotechnology industry, categorized as a Micro Cap company.<BR><BR>History: <BR>Checkpoint Trends Ltd was established in 1991 and was formerly known as Rubra Medicaments Ltd. The company name was changed in April 2022. The latest quarterly results reported net sales and net profit of 0 Cr for the period ending March 2025.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 0 Cr (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 0 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: Rs 9 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 10.00 <BR>Industry P/E: 35 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: -0.04 <BR>Return on Equity: 1.71% <BR>Price to Book: 9.70 <BR><BR>Contact Details: <BR>Address: 604 6th Floor Meghdoot, Mogul Lines Staff CHSL JVPD Sc Mumbai Maharashtra : 400049 <BR>Tel: 91-9167469649 <BR>Email: rubraltd@gmail.com <BR>Website: http://www.rubramed.com

Has Checkpoint Trend declared dividend?

No Dividend History Available

Who are the peers of the Checkpoint Trend?

Peers of Checkpoint Trend include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, and others. Checkpoint Trend has a 1-year return of 110.41%, outperforming its peers, while management risk varies from excellent to below average across the group.

Peers: The peers of Checkpoint Trend are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Unjha Formul., Vivanza Biosci., Cian Healthcare, Beryl Drugs, and Ortin Global.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Good management risk is found at Divi's Lab., Torrent Pharma, and the rest. Average management risk is noted at Unjha Formul., Cian Healthcare, Beryl Drugs, and Ortin Global, while Below Average management risk is seen at Vivanza Biosci. and Checkpoint Trend. Growth is Excellent for Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, Below Average for Divi's Lab., Torrent Pharma, Unjha Formul., Cian Healthcare, Beryl Drugs, Ortin Global, and Checkpoint Trend, and Below Average for Vivanza Biosci. Capital Structure is Excellent for Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, Good for Torrent Pharma and Unjha Formul., and Below Average for Divi's Lab., Vivanza Biosci., Checkpoint Trend, Cian Healthcare, Beryl Drugs, and Ortin Global.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Divi's Lab. at 51.69%, while the peer with the lowest is Vivanza Biosci. at -60.94%. Checkpoint Trend's own 1-year return is 110.41%, which is significantly higher than all peers. Additionally, Unjha Formul., Vivanza Biosci., Cian Healthcare, Beryl Drugs, and Ortin Global all have negative six-month returns.